Trilogy Global Advisors Lp Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Trilogy Global Advisors Lp reduced its stake in Amgen by 4.61% during the most recent quarter end. The investment management company now holds a total of 343,747 shares of Amgen which is valued at $59,241,358 after selling 16,618 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Amgen makes up approximately 1.73% of Trilogy Global Advisors Lp’s portfolio.

Other Hedge Funds, Including , Pittenger Anderson Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 6,255 additional shares and now holds a total of 22,230 shares of Amgen which is valued at $3,831,118. Amgen makes up approx 0.42% of Pittenger Anderson Inc’s portfolio.Palisades Hudson Asset Management reduced its stake in AMGN by selling 297 shares or 13.25% in the most recent quarter. The Hedge Fund company now holds 1,945 shares of AMGN which is valued at $337,769. Amgen makes up approx 0.26% of Palisades Hudson Asset Management’s portfolio.Td Asset Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 6,542 additional shares and now holds a total of 426,982 shares of Amgen which is valued at $74,149,694. Amgen makes up approx 0.13% of Td Asset Management Inc’s portfolio.Waverton Investment Management Ltd boosted its stake in AMGN in the latest quarter, The investment management firm added 510 additional shares and now holds a total of 12,504 shares of Amgen which is valued at $2,151,063. Amgen makes up approx 0.16% of Waverton Investment Management Ltd’s portfolio.Gargoyle Investment Advisor L.l.c. boosted its stake in AMGN in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 18,756 shares of Amgen which is valued at $3,201,274. Amgen makes up approx 1.13% of Gargoyle Investment Advisor L.l.c.’s portfolio.

Amgen opened for trading at $172.01 and hit $174.5 on the upside on Wednesday, eventually ending the session at $174.31, with a gain of 1.25% or 2.15 points. The heightened volatility saw the trading volume jump to 25,80,941 shares. Company has a market cap of $130,447 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.